Achieve Life Sciences Appoints New CEO, Overhauls Board, and Confirms Regulatory Delay for Lead Product

summarizeSummary

Achieve Life Sciences announced a new CEO, significant board changes, and the formal closure of a major private placement, while also confirming an expected FDA Complete Response Letter for cytisinicline, delaying its U.S. launch.

check_boxKey Events

• New CEO and Board Leadership Appointed

  Andrew D. Goldberg, MD, has been appointed Chief Executive Officer and a Board member. Lucian Iancovici, MD, will assume the role of Chairman of the Board, and Christopher Martin was appointed as a new director, nominated by Frazier Life Sciences following the recent private placement.

• Chief Commercial Officer Departs

  Jaime Xinos, the Chief Commercial Officer, will depart the company effective May 31, 2026, as part of a commercial leadership reorganization.

• Regulatory Delay Confirmed for Cytisinicline

  The company expects to receive a Complete Response Letter (CRL) from the FDA by June 20, 2026, for its cytisinicline NDA due to issues at a third-party manufacturing facility. Resubmission is now planned for Q4 2026, pushing the U.S. commercial launch target to the first half of 2027.

• Private Placement Officially Closed

  The previously announced private placement has closed, providing $180 million upfront and potential for an additional $174 million from milestone-based warrants. This significantly boosts the company's cash reserves, with estimated net proceeds of approximately $168.6 million.

auto_awesomeAnalysis

This filing details a significant leadership transition, including the appointment of a new Chief Executive Officer and changes to the Board of Directors, which are critical for the company's strategic direction. Concurrently, it confirms a material delay in the regulatory pathway for their lead product, cytisinicline, with an expected Complete Response Letter from the FDA and a revised launch timeline. The formal closure of a substantial private placement provides crucial capital, addressing prior 'going concern' warnings and funding future operations, balancing the negative impact of the regulatory setback.